Alexis Talbot

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026

Five trials reshaping multiple myeloma.

Five trials reshaping multiple myeloma.

Journal: Med (New York, N.Y.)
Published: May 01, 2026

Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives.

Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives.

Journal: Autoimmunity reviews
Published: January 01, 2026

CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.

CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.

Journal: HemaSphere
Published: November 28, 2025

Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.

Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Cardiac Phenotype and Clinical Outcomes in Randall Disease versus Light-Chain Amyloidosis.

Cardiac Phenotype and Clinical Outcomes in Randall Disease versus Light-Chain Amyloidosis.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: November 21, 2025

Bispecific T-cell engagers for the treatment of autoimmune diseases: Current status and therapeutic perspectives

Bispecific T-cell engagers for the treatment of autoimmune diseases: Current status and therapeutic perspectives

Journal: La Revue de medecine interne
Published: October 02, 2025

Oral hemorrhagic bullae as the initial manifestation of AL amyloidosis.

Oral hemorrhagic bullae as the initial manifestation of AL amyloidosis.

Journal: Annales de dermatologie et de venereologie
Published: September 15, 2025

B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization.

B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA Sensitization.

Journal: Kidney international
Published: September 13, 2025

Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature.

Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature.

Journal: Immunotherapy
Published: August 21, 2025

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Journal: JMIR formative research
Published: August 07, 2025
Showing 1-12 of 75

Last Updated: 09/26/2026